Table 1 Baseline and treatment characteristics of patients grouped by BM status
Patients without BM (n = 127) | Patients developing metachronous BM (n = 30) | |||
|---|---|---|---|---|
Characteristic | NO. | % | NO. | % |
Age, years | ||||
≤ 49 | 24 | 18.9 | 12 | 40.0 |
> 49 | 103 | 81.1 | 18 | 60.0 |
Median (Range) | 60 (28–93) | 54 (33–75) | ||
Gender | ||||
Male | 63 | 49.6 | 14 | 46.7 |
Female | 64 | 50.4 | 16 | 53.3 |
KPS score | ||||
≥ 80 | 115 | 90.5 | 30 | 100 |
< 80 | 12 | 9.5 | 0 | 0 |
Histology | ||||
Adenocarcinoma | 122 | 96.1 | 28 | 93.3 |
Non-adenocarcinoma | 5 | 3.9 | 2 | 6.7 |
BMI | ||||
Mean (95%CI) | 21.9 (14.9–28.8) | 22.7 (16.3–29.2) | ||
Smoking status | ||||
Yes | 42 | 33.1 | 8 | 26.7 |
No | 85 | 66.9 | 22 | 73.3 |
CEA (ng/ml) | ||||
Median (Range) | 23.5 (0.5–8048) | 30.5 (1.5–1819) | ||
CA125 (ng/ml) | ||||
Median (Range) | 52.9 (4.76–3369) | 69.4 (11.3–954.5) | ||
NSE (ng/ml) | ||||
Median (Range) | 15.0 (4.4–133.1) | 15.2(7.6–55.2) | ||
First-line treatment regimen | ||||
EGFR-TKI treatment | 112 | 88.2 | 21 | 70 |
Chemotherapy | 15 | 11.8 | 9 | 30 |
Type of EGFR mutations | ||||
L858R | 49 | 38.6 | 14 | 46.7 |
19 deletion | 67 | 52.8 | 11 | 36.7 |
Othera | 11 | 8.6 | 5 | 16.7 |
NO. of extracranial metastases | ||||
0 | 8 | 6.3 | 2 | 6.7 |
1 | 65 | 51.2 | 14 | 46.7 |
2 | 42 | 33.1 | 10 | 33.3 |
3 or more | 12 | 9.4 | 4 | 13.3 |
Clinical stages | ||||
Stage IIIB | 8 | 6.3 | 2 | 6.7 |
Stage IV | 119 | 93.7 | 28 | 93.3 |
Location of extracranial metastatic sites | ||||
Pleural effusion | 8 | 6.3 | 6 | 20.0 |
Liver | 17 | 13.4 | 4 | 13.3 |
Adrenal | 17 | 13.4 | 1 | 3.3 |
Bone | 73 | 57.5 | 18 | 60 |
Lung | 75 | 59.1 | 17 | 56.6 |
Other | 12 | 9.4 | 2 | 6.7 |
Types of EGFR-TKIs | ||||
Gefitinib | 80 | 63.0 | 19 | 63.3 |
Erlotinib | 31 | 24.4 | 7 | 23.3 |
Icotinib | 16 | 12.6 | 4 | 13.4 |
Local therapy for BM | ||||
None | NA | 8 | 26.7 | |
WBRT | NA | 14 | 46.7 | |
SRS | NA | 8 | 26.6 | |